Presenters
Endocrinologist
Prof. Alexander Tan, MD
Course Details
The aim of this webinar is to provide updates on how Linagliptin simplifies type 2 diabetes management and how it stands out versus other dipeptidyl peptidase-4 (DPP4) inhibitors. It will discuss the clinical data and real-world evidence supporting its proven consistent efficacy and safety across a broad range of patients. Furthermore, the different renal excretion rate of DPP4i will be discussed and how the lowest renal excretion rate of Linagliptin truly offers no dose adjustment for its patients.
Estimated time of Completion: 28 mins.
CPD Points: 1 Point
PRC Program No: PROG-2023-59764
Not all DPP4i are the Same Course Outline
- Linagliptin pharmacokinetics and pharmacodynamics
- Efficacy of Linagliptin regardless of age, disease duration, BMI, ethnicity, kidney & liver function and T2D therapy
- Linagliptin demonstrated long-term CV and renal safety in a broad range of patients
- Linagliptin is the only DPP4i with the lowest renal excretion rate which truly offers no dose adjustment for T2D patients
PC-PH-105088 / July 2023